bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.94 USD
-0.08 (-7.57%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $0.93 -0.01 (-1.36%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
bluebird bio, Inc. [BLUE]
Reports for Purchase
Showing records 441 - 460 ( 533 total )
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 25th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
As Expected, SCD Patient Treated with LentiGlobin on Track to Cure, Reiterate OUTPERFORM Rating and $222 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
As Expected, SCD Patient Treated with LentiGlobin on Track to Cure, Reiterate OUTPERFORM Rating and $222 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary SCD Data Suggests a Potential for a Functional Cure
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Earlier Launch Timing on Regulatory Update, Expect Additional Positive Newsflow with Release of EHA Abstracts this Week, Raising PT to $222
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Rapid Enrollment Points to Increasing Confidence on Safety Profile
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 Results, Awaiting Sickle Cell Data at EHAC, Abstracts Available May 21, Maintain OP rating
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
SCD Data at ASH Makes The Most Clinical Sense
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - The State of Immunotherapy 3.0: "Silver Linings Immunobook"; Bright Horizons
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Independent Validation and the Continued Resurgence in Gene Therapy
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals: History Points to Limited Impact from Fed Rate Hikes and Heightened Volatility
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 13th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L